Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

Pheochromocytoma and the normal adrenal medulla: improved visualization with I-123 MIBG scintigraphy

Conference · · Radiology; (United States)
OSTI ID:5483140
The radiopharmaceutical iodine 131 metaiodobenzylguanidine (I-131 MIBG) has been shown to locate pheochromocytomas scintigraphically with a false-negative rate of approximately 13%. To improve image quality and reduce the false-negative rate, I-123 was examined as a radioactive label for MIBG, as it has many advantages over I-131, including superior dosimetry and better detection efficiency. Diagnostic doses of 0.5 mCi (18.5 MBq) I-131 MIBG and 10.0 mCi(370.0 MB1) I-123 MIBG with nearly equivalent radiation dosimetries were compared in 18 patients with known or suspected pheochromocytomas. Images of superior quality were obtained with I-123 MIBG in 18 of 18 patients, and in eight cases lesions not visualized on I-131 MIBG scintigraphy were portrayed. A further advantage of I-123 MIBF is that it permits single photon emission computed tomography (SPECT).
Research Organization:
Univ. of Michigan, Ann Arbor
OSTI ID:
5483140
Report Number(s):
CONF-851152-
Conference Information:
Journal Name: Radiology; (United States) Journal Volume: 155:3
Country of Publication:
United States
Language:
English